---
layout: post
title: New Drug Approvals - Pt. XXIV - Bepotastine Besilate (Bepreve)
date: '2010-01-17T07:55:00.004Z'
author: Patricia
tags:
- 2009 New Drugs
modified_time: '2010-01-17T22:11:44.991Z'
thumbnail: http://1.bp.blogspot.com/_GrFxGiayAGE/S1CL_f1JSgI/AAAAAAAAAXk/vTthGFQ25TM/s72-c/Bepreve.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-2147082115136740452
blogger_orig_url: http://chembl.blogspot.com/2010/01/new-drug-approvals-pt-bepotastine.html
---

<a href="http://1.bp.blogspot.com/_GrFxGiayAGE/S1CL_f1JSgI/AAAAAAAAAXk/vTthGFQ25TM/s1600-h/Bepreve.jpg" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}"><img alt="" id="BLOGGER_PHOTO_ID_5426991473973873154" src="http://1.bp.blogspot.com/_GrFxGiayAGE/S1CL_f1JSgI/AAAAAAAAAXk/vTthGFQ25TM/s320/Bepreve.jpg" style="margin: 0px auto 10px; cursor: pointer; display: block; height: 188px; text-align: center; width: 200px;" border="0" /></a><a href="http://4.bp.blogspot.com/_GrFxGiayAGE/S1CMEac8b8I/AAAAAAAAAXs/MZIbhiH0-zA/s1600-h/Bepotastine_Icons.png" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}"><img alt="" id="BLOGGER_PHOTO_ID_5426991558429536194" src="http://4.bp.blogspot.com/_GrFxGiayAGE/S1CMEac8b8I/AAAAAAAAAXs/MZIbhiH0-zA/s320/Bepotastine_Icons.png" style="margin: 0px auto 10px; cursor: pointer; display: block; height: 37px; text-align: center; width: 320px;" border="0" /></a>

We're mopping up a few drug approvals from 2009 we have not yet covered yet as monographs...



Approved on September 8th 2009 was Bepotastine Besilate, marketed under the trade name Bepreve. Bepotastine is a topical, selective and non-sedating <a href="http://www.uniprot.org/uniprot/P35367">histamine (H1) receptor</a> antagonist indicated in the treatment of itching associated with allergic conjunctivitis. Through the H1 binding, Bepotastine has broad range of anti-inflammatory effects - a stabilizing effect on mast cells, inhibition of <a href="http://en.wikipedia.org/wiki/Eosinophil_granulocyte">eosinophil</a> migration and <a href="http://en.wikipedia.org/wiki/Interleukin_5">interleukin-5 (IL-5)</a>, <a href="http://en.wikipedia.org/wiki/Leukotriene_B4">leukotriene B4 (LTB4)</a> and <a href="http://en.wikipedia.org/wiki/Platelet-activating_factor">platelet activating factor (PAF)</a> release. Bepotastine has been previously approved in Japan, under the trade name Talion, for allergic rhinitis (2000) and urticaria and skin pruritus (2002).



Bepotastine is a chirally pure, synthetic small molecule drug (Molecular Weight 388.89 g.mol-1 for Bepotastine itself and 547.06 g.mol-1 for the dosed besilate salt), is Rule-of-Five compliant and is delivered as an ophthalmic solution. Bepotastine has a low protein binding of approximately 55%, is minimally metabolized by CYP450 isozymes and elimination is mainly through renal excretion (approximately 75-90% excreted unchanged in urine). The recommended dosage is one drop directly to the infected eye(s) twice a day.



The prescribing information can be found <a href="http://www.istavision.com/pdf/Bepreve_insert.pdf">here</a>.



<a href="http://1.bp.blogspot.com/_GrFxGiayAGE/S1CR3pP0aOI/AAAAAAAAAX0/j74kKPQ2ixA/s1600-h/Bepotastine.png" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}"><img alt="" id="BLOGGER_PHOTO_ID_5426997936132483298" src="http://1.bp.blogspot.com/_GrFxGiayAGE/S1CR3pP0aOI/AAAAAAAAAX0/j74kKPQ2ixA/s320/Bepotastine.png" style="margin: 0px auto 10px; cursor: pointer; display: block; height: 138px; text-align: center; width: 225px;" border="0" /></a>The structure (+)-4-[[(S)-p-chloro-alpha-2-pyridylbenzyl]oxy]-1-piperidine butyric acid, with no unusual reactive features. There is a single stereocenter in the structure, and Bepotastine is dosed as the (+) enantiomer. The physicochemistry will be dominated by the Zwitterionic nature of the molecule - a molecule of nett neutral charge, but which contains compensatory charge centers - in this case the basic nitrogen of the central piperidine ring, and the carboxylic acid (on the far right of the compound figure).



<pre>NAME="Bepotastine"
DRUG_TARGET="<span class="Apple-style-span" style="white-space: pre-wrap;">MSLPNSSCLLEDKMCEGNKTTMASPQLMPLVVVLSTICLVTVGLNLLVLYAVRSERKLHT</span></pre><pre style="white-space: pre-wrap; word-wrap: break-word;">VGNLYIVSLSVADLIVGAVVMPMNILYLLMSKWSLGRPLCLFWLSMDYVASTASIFSVFI
LCIDRYRSVQQPLRYLKYRTKTRASATILGAWFLSFLWVIPILGWNHFMQQTSVRREDKC
ETDFYDVTWFKVMTAIINFYLPTLLMLWFYAKIYKAVRQHCQHRELINRSLPSFSEIKLR
PENPKGDAKKPGKESPWEVLKRKPKDAGGGSVLKSPSQTPKEMKSPVVFSQEDDREVDKL
YCFPLDIVHMQAAAEGSSRDYVAVNRSHGQLKTDEQGLNTHGASEISEDQMLGDSQSFSR
TDSDTTTETAPGKGKLRSGSNTGLDYIKFTWKRLRSHSRQYVSGLHMNRERKAAKQLGFI
MAAFILCWIPYFIFFMVIAFCKNCCNEHLHMFTIWLGYINSTLNPLIYPLCNENFKKTFK
RILHIRS"</pre><pre>SMILES="Clc1ccc(cc1)C(OC2CCN(CCCC(=O)O)CC2)c3ncccc3"
InChI="InChI=1S/C21H25ClN2O3/c22-17-8-6-16(7-9-17)21(19-4-1-2-12-23-19)27-18-
10-14-24(15-11-18)13-3-5-20(25)26/h1-2,4,6-9,12,18,21H,3,5,10-11,
13-15H2,(H,25,26)"
InChIKey="YWGDOWXRIALTES-UHFFFAOYSA-N"
ChemDraw=http://www.ebi.ac.uk/chembl/downloads/Bepotastine.cdx
</pre><pre></pre>Bepreve is marketed by <a href="http://www.istavision.com/">IstaVision</a> and the product website is <a href="http://www.istavision.com/products/products_bepreve.asp">here</a>